General Home Investors News Uzedy

MedinCell’s partner Teva provides additional information regarding the New Drug Application for mdc-IRM

By MedincellMay 3, 2022March 15th, 2024No Comments

MedinCell’s partner Teva provides additional information regarding the New Drug Application for mdc-IRM

May 3, 2022

Previous PostMedinCell: US Pharma Development expert Richard Malamut, MD becomes Chief Medical Officer
Next PostMedinCell provides additional information regarding the new drug application for mdc-IRM

Better medicine for all

Website by ScreenUp